24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
IBRULIEVA 140MG is an Capsule medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | IBRULIEVA 140MG |
|---|---|
| Composition | Ibrutinib Capsules 140mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsule |
| Packaging | Btl (30 cap) |
| Country of Origin | India |
Ibrutinib Capsules 140mg (Ibrutinib Capsules 140mg) is a widely used Capsule medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
IBRULIEVA contains Ibrutinib, a first-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It blocks BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
Ibrutinib is indicated for the treatment of:
1. Chronic Lymphocytic Leukemia (CLL)
2. Small Lymphocytic Lymphoma (SLL)
3. Mantle Cell Lymphoma (MCL) – after at least one prior therapy
4. Waldenström’s Macroglobulinemia
5. Marginal Zone Lymphoma (MZL) – after prior anti-CD20 therapy
Common side effects:
• Diarrhea
• Fatigue
• Muscle and joint pain
• Nausea
• Rash
Hematological:
• Neutropenia
• Thrombocytopenia
• Anemia
Serious side effects:
• Bleeding events
• Atrial fibrillation
• Severe infections
• Hypertension
Dosage varies by indication:
• CLL/SLL/Waldenström’s: 420 mg once daily
• MCL/MZL: 560 mg once daily
Take capsules once daily at the same time, swallow whole with water.
Can be taken with or without food.
NOTE: This medicine should be taken only under a doctor’s supervision.